Trametinib is a mitogen-activated protein kinase 1 MEK1/MEK2 inhibitor that inhibits ERK phosphorylation in the RAS pathway and has demonstrated a reduction in NRAS-mutated AML proliferation in pre-clinical studies [94]. This evidence concerns the gene MAP2K1 and acute myeloid leukemia.